Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

2NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSSeptember 30, 2010December 31, 2009 (1)Current assets:Cash and cash equivalents

$
2,906$
49,597Short-term investments

290,396346,614Accounts receivable

5,5534,801Inventory

11,4606,471Other current assets

6,1196,183Total current assets

$
326,434$
413,666Property and equipment, net

97,68678,263Goodwill

76,50176,501Other assets

1,8557,088Total  assets

$
502,476$
575,518LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
4,403$
3,066Accrued compensation

10,55210,052Accrued expenses

12,3524,354Accrued clinical trial expenses

12,75914,167Deferred revenue, current portion

40,232115,563Interest payable

581,805Other current liabilities

4,4764,009Total current liabilities

$
84,832$
53,016Convertible subordinated notes

214,955214,955Capital lease obligations

17,40218,800Deferred revenue

69,03376,809Deferred gain

4,3715,027Other long-term liabilities

4,9364,544Total liabilities

$
395,529$
473,151Commitments and contingenciesStockholders' equity:Preferred stock

$
-$
-Common stock

99Capital in excess of par value

1,347,8001,327,942Accumulated other comprehensive income

1,1051,025Accumulated deficit

(1,241,967)(1,226,609)Total stockholders' equity

$
,947$
2,367Total liabilities and stockholders' equity

$
502,476$
575,518(1) The consolidated balance sheet at December 31, 2009 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  TeamHealth Medical Call Center (THMCC), ... nurse advice lines, announces its newly formed Clinical ... and administrative leaders, provides clinical expertise to advance ... services for hospital clients, physician clients and patients. ... evolves, it,s imperative to continuously advance our services ...
(Date:5/23/2013)... 2013 More than half of women diagnosed ... chemotherapy and still have excellent outcomes. To educate women, ... the largest sources of online consumer information about breast ... page provide recently diagnosed women with information sources, to ... "We anticipate these innovative social media campaigns ...
(Date:5/23/2013)... , May 23, 2013 Anthem Blue ... that would have required them to obtain their medications ... Consumer Watchdog and Whatley Kallas LLC.  ... Court, alleged that Blue Cross,s mandatory mail order program ... their health and privacy. "This settlement brings ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
(Date:5/25/2013)... 25, 2013 Pradaxa lawsuits ... episodes of internal bleeding while using the blood thinner continue ... Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... side effect claims had been filed in the ... 705 claims reported by the Court on May 15th. ( ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May ... brain cancer research and advocacy, comments on a new ... that shows incorporating cold atmospheric plasma into brain cancer ... , According to a Science Daily article, ... (MPE), biologists and physicians demonstrated the “synergistic effect of ...
(Date:5/25/2013)... Dr. Farooq Ashraf, founder of the Atlanta Vision ... his practice’s adoption of The iFS Advanced Femtosecond Laser. ... proven with more than 10 years of clinical research ... “We are happy to announce that we will now ... LASIK practice,” Ashraf said Thursday. “We have been using ...
(Date:5/25/2013)... The Slim Weight Patch has been clinically proven many ... to the highly sought after ingredients that have been used ... extra 2 months supply & premium membership of Slimming+ to ... you desire faster than ever. , Click Here to ... weight patch consumers can observe instant results within only a ...
(Date:5/25/2013)... For college students, few events ... they are turning to prescription stimulants like Adderall ... more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . ... that students who pick up Adderall, “just to ... developing a physical and psychological dependency. While initially ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... 12 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today that it will report fourth-quarter ... for 2009 on Monday, January 26, before the market ... investors to discuss the results beginning at 8:30 a.m. ...
... Lilly and Company,(NYSE: LLY ) today filed ... (SEC) detailing the pro forma impact of the company,s ... available on the,SEC,s website at www.sec.gov and ... www.investor.lilly.com . , The content ...
... VANCOUVER, Jan. 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ... million for the quarter and $141.9 million for the full ... quarter declined by 32.7% over the same quarter in 2007 ... annual sales in 2007. Sales in the U.S. for the ...
... Ranir, LLC, a leading,consumer products oral care company, ... foremost manufacturer and marketer of interdental oral,care products ... San Diego,California, Placontrol is the founder of the ... disclosed. , Ranir, headquartered ...
... Genomma Lab Internacional,S.A.B. de C.V. (BMV: LAB) ("Genomma ... the Company signed an agreement with IXE Casa de ... for the Company,s outstanding shares, thus,becoming another company to ... valid upon approval of the Mexican Stock Exchange (Bolsa,Mexicana ...
... has negative impact- No similar material exposures are expected ... wins are strong; service revenue expected to increase by ... Corporation (Nasdaq: PRXL ) has received notification ... unable to continue to make payments that are due ...
Cached Medicine News:Health News:Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results 2Health News:QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008 2Health News:Ranir, LLC Announces the Acquisition of Placontrol, Inc. 2Health News:Genomma Lab, New Participant in Market-Maker Program 2Health News:PAREXEL Reports Preliminary Second Quarter Results 2Health News:PAREXEL Reports Preliminary Second Quarter Results 3Health News:PAREXEL Reports Preliminary Second Quarter Results 4Health News:PAREXEL Reports Preliminary Second Quarter Results 5Health News:PAREXEL Reports Preliminary Second Quarter Results 6
The OneTouch Flexx Professional Blood Glucose Monitoring System with OneTouchPro Test Strips sets the standard for safety and convenience with unique off-meter sample application and a wide range of ...
... the market in New Technology, the Arrow ... whole new first and only IABP system ... a physiologically based timing algorithm, WAVE, to ... accuracy. Second generation Automaticity provides for ...
... NEXES Special Stains automated system ... to provide enhanced consistency of ... stains. Proprietary kinetic technology, including ... Mixing, assures high quality routine ...
... NexES IHC, the worlds first ... staining system introduced a whole ... while combining system modularity and ... laboratory productivity. The NexES Systems ...
Medicine Products: